Multiple Myeloma
Multiple Myeloma Market

Multiple Myeloma is a cancer of plasma cells; when these plasma cells become cancerous and grow out of control, this is known as Multiple Myeloma. The plasma cells produce an abnormal protein (antibody) known by different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein.


Multiple Myeloma Epidemiological Segmentation 

The Epidemiological Segmentation of Multiple Myeloma in 8MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of Multiple Myeloma 
  • Total Symptomatic Cases of Multiple Myeloma
  • Gender-Specific Cases of Multiple Myeloma
  • Diagnosed Cases of Multiple Myeloma by Age Distribution
  • Cases of Multiple Myeloma by Treatment Line 


Multiple Myeloma Epidemiology 

  • The total incident cases of Multiple Myeloma in 8MM in 2017 was 85,971 
  • The incident cases of Multiple Myeloma in the United States in 2017 was 30,271  


Multiple Myeloma Market

The market of Multiple Myeloma in 8MM in 2017 was USD 14,111 million  


Multiple Myeloma Market Drivers

  • Increasing incidence rate
  • The high adoption rate of newer therapies
  • Increase in the Geriatric Population


Multiple Myeloma Market Barriers

  • Expensive treatment options for Multiple Myeloma 
  • Toxicities and adverse events of various Multiple Myeloma therapeutics 

 

Multiple Myeloma Emerging Drugs

The emerging drugs of the Multiple Myeloma market are 

  • Belantamab Mafodotin (GSK2857916)
  • Idecabtagene vicleucel (bb2121/ ide-cel)
  • Venetoclax (ABT-199)
  • JNJ-68284528 (LCAR-B38M/JNJ-4528)
  • Melflufen (melphalan flufenamide)
  • Keytruda (Pembrolizumab)
  • Cetrelimab (JNJ-63723283)
  • REGN5458
  • Iberdomide (CC-220)
  • Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy
  • Encorafenib in combination with Binimetinib
  • CLR 131 (131-CLR1404)
  • NY-ESO-1C259T Cells
  • BL-8040
  • GVAX (GM-CSF) Vaccine
  • ECT-001 
  • TAK-079
  • GBR 1342 (ISB 1342)
  • P-BCMA-101 CAR-T cells
  • Opdivo (Nivolumab)
  • AMG 420 (BI 836909)
  • PBCAR269A
  • JCARH125 (Orvacabtagene autoleucel; Orva-cel)
  • MP0250
  • Teclistamab (JNJ-7957; JNJ-64007957)
  • Descartes-11
  • Imfinzi (Durvalumab)
  • Imbruvica (Ibrutinib) 
  • Felzartamab (MOR202)
  • Chidamide (Epidaza) 

And many others.  


Multiple Myeloma Key Players

The key players in the Multiple Myeloma market are

  • GlaxoSmithKline
  • Bristol-Myers Squibb/Bluebird bio
  • AbbVie and Roche
  • Janssen Biotech/Nanjing Legend Biotech
  • Oncopeptides AB
  • Merck Sharp & Dohme Corp
  • Janssen Research & Development
  • Regeneron Pharmaceuticals
  • Celgene
  • P-BCMA-101 CAR-T cells
  • RAPA Therapeutics
  • Pfizer (Array Biopharma)
  • Cellectar Biosciences
  • Adaptimmune Therapeutics 
  • BioLineRx
  • Aduro Biotech
  • ExCellThera
  • Takeda
  • Glenmark (Ichnos Sciences SA)
  • Poseida Therapeutics
  • Amgen
  • Precision BioSciences
  • Juno Therapeutics (a Bristol-Myers Squibb company)
  • Molecular Partners AG
  • Cartesian Therapeutics
  • AstraZeneca
  • Abbvie (Pharmacyclics) and Johnson & Johnson
  • MorphoSys AG/I-Mab Biopharma
  • Chipscreen Biosciences 

And many others.